April 24th 2024
The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug, or ibuprofen.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Uro Pipeline: 1st patients treated in phase III study of investigational BPH Tx
January 1st 2016Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Non-adherence to stone meds raises hospitalization risk
December 1st 2015When it comes to urinary stone disease, it appears that prescribers know what they’re doing. According to a study presented at the World Congress of Endourology and SWL in London, non-adherence to kidney stone medications led to a significant increase in adverse health outcomes.
Single-use ureteroscope yields high-quality images
December 1st 2015Findings from preclinical studies evaluating the performance of an investigational single-use digital flexible ureteroscope (Lithovue, Boston Scientific) support it as a viable alternative to current non-disposable flexible digital and fiberoptic ureteroscopes, said Brian H. Eisner, MD, at the World Congress of Endourology and SWL in London.
Novel artificial sphincter may overcome disadvantages of gold standard
November 2nd 2015A novel artificial urinary sphincter is safe and effective in men with stress urinary incontinence, according to data from a small study presented at the International Continence Society annual meeting in Montreal.
Breaking new ground (and kidney stones) with ultrasound
November 1st 2015Novel ultrasound-based techniques for propelling and breaking kidney stones could soon join ESWL and URS in the urologist’s treatment armamentarium. In this interview, Michael Bailey, PhD, discusses how these technologies work, what they’re capable of, and where they are in development.
Product Update: HIFU cleared, compact catheter launched
November 1st 2015Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.
Risk calculator predicts breakthrough UTIs in reflux patients
September 24th 2015A new study on the use of a reflux calculator, developed at Children’s Hospital of Orange County in Irvine, CA, suggests the web-based risk stratification and probability model helps to predict vesicoureteral reflux patients’ 2-year risk of breakthrough urinary tract infection.
BPH modality may offer efficient option
September 1st 2015A novel treatment for the targeted removal of prostate tissue may soon be coming to a hospital near you. According to the results of a phase II study presented at the AUA annual meeting in New Orleans, Aquablation, a minimally invasive water ablation therapy, demonstrated efficient and precise resection of prostate tissue in patients with BPH.
Study: BPH procedure’s benefits sustained at 3 years
September 1st 2015The prostatic urethral lift (PUL [UroLift, NeoTract, Inc.]) yields successful 3-year durability and superior rate of improvement of BPH symptoms compared to transurethral resection of the prostate, according to separate studies presented at the AUA annual meeting in New Orleans.